Edition:
India

Interpace Diagnostics Group Inc (IDXG.OQ)

IDXG.OQ on NASDAQ Stock Exchange Capital Market

1.02USD
14 Dec 2018
Change (% chg)

$0.02 (+2.00%)
Prev Close
$1.00
Open
$1.00
Day's High
$1.02
Day's Low
$0.97
Volume
16,692
Avg. Vol
75,163
52-wk High
$1.78
52-wk Low
$0.77

Latest Key Developments (Source: Significant Developments)

Interpace Diagnostics Group Inc Files For Mixed Shelf Of Upto $50 Million - SEC Filing
Saturday, 6 Oct 2018 

Oct 5 (Reuters) - Interpace Diagnostics Group Inc ::INTERPACE DIAGNOSTICS GROUP INC FILES FOR MIXED SHELF OF UPTO $50 MILLION - SEC FILING.  Full Article

Interpace Diagnostics Announces Reimbursement Expansion Of Thygenext
Monday, 24 Sep 2018 

Sept 24 (Reuters) - Interpace Diagnostics Group Inc ::INTERPACE DIAGNOSTICS ANNOUNCES REIMBURSEMENT EXPANSION OF THYGENEXT™.INTERPACE DIAGNOSTICS GROUP - GETS APPROVAL TO LAUNCH THYGENEXT, IN STATES OF PENNSYLVANIA AND NEW YORK.INTERPACE DIAGNOSTICS GROUP - PENNSYLVANIA APPROVAL IS FINAL, NEW YORK STATE APPROVAL CONDITIONED UPON RECEIPT OF ADDITIONAL INFORMATION REQUESTED.  Full Article

Interpace Diagnostics Group Q1 Revenue Rises 39 Percent
Tuesday, 15 May 2018 

May 15 (Reuters) - Interpace Diagnostics Group Inc ::INTERPACE DIAGNOSTICS GROUP REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS, BUSINESS PROGRESS AND RECENT ACCOMPLISHMENTS.Q1 REVENUE ROSE 39 PERCENT TO $4.8 MILLION.QTRLY LOSS PER SHARE $0.11.  Full Article

Interpace Diagnostics says ‍New York State Department Of Health approved its TERT service offering​
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Interpace Diagnostics Group Inc -:Interpace Diagnostics Group Inc- ‍New York State Department Of Health has reviewed and approved for marketing co's TERT service offering​.  Full Article

Interpace Diagnostics says Q3 sales up 27 pct
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Interpace Diagnostics Group Inc ::Interpace diagnostics group reports third quarter 2017 financial results, business progress and recent accomplishments.Q3 sales rose 27 percent to $4.2 million.Interpace diagnostics group inc qtrly ‍net loss per diluted share of common stock $0.15​.  Full Article

Interpace Diagnostics announces national contract with Aetna
Wednesday, 28 Jun 2017 

June 28 (Reuters) - Interpace Diagnostics Group Inc :Interpace Diagnostics announces national contract with Aetna.Interpace Diagnostics Group -Signed new national contract with Aetna for its THYGENX and Thyramir molecular tests for indeterminate thyroid nodules​.  Full Article

Interpace Diagnostics files for offering of up to $13.8 mln
Monday, 22 May 2017 

May 22 (Reuters) - Interpace Diagnostics Group Inc ::Files for offering of up to $13.8 million .Interpace Diagnostics Group - offering for shares of co's common stock and pre-funded warrants to purchase shares of its common stock.  Full Article